Acute Myeloid Leukemia | Unmet Need | First-Line Intensive-Induction-Eligible | US/FR/DEU/UK | 2023

Acute myeloid leukemia (AML) is the most common acute leukemia in adults, originating from mutant myeloid precursor cells. Presently, the AML drug market is dominated by chemotherapy backbones, but recent drug approvals suggest a shift toward targeted agents. Approximately 70% of patients treated with cytotoxic chemotherapy achieve complete remission. Nevertheless, the five-year relative survival rate is only 30.5%. In this report, we focus on the unmet need in the first-line treatment of intensive-induction-eligible AML. These patients currently receive cytotoxic chemotherapy, with or without biomarker-driven targeted therapies (such as Mylotarg and Rydapt) or the topoisomerase II inhibitor Vyxeos.

QUESTIONS ANSWERED

• What treatment drivers and goals are most important to surveyed hematologist-oncologists when selecting a first-line therapy for intensive-induction-eligible AML?
• How do key currently available regimens, including Vyxeos or Rydapt in combination with intensive chemotherapy, perform in terms of key attributes?
• What are the greatest unmet needs and most attractive opportunities in the first-line treatment of intensive-induction-eligible AML?
• What tradeoffs are surveyed hematologist-oncologists willing to make for new and emerging therapies to treat this subpopulation of AML?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 62 U.S. and 31 European hematologist-oncologists fielded in December 2022.

Key companies: Pfizer, Novartis, Jazz Pharmaceuticals

Key drugs: Mylotarg, Rydapt, Vyxeos, cytarabine, daunorubicin, fludarabine, G-CSF, and idarubicin